Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Ad image

Zymo Research and BluMaiden Biosciences Announce Partnership to Provide Clinical Trial Analysis and Reporting Services to the Pharmaceutical Sector

MONews
4 Min Read

Zymo Research Corporation and BluMaiden Biosciences are collaborating to provide end-to-end clinical trial analytics and reporting services based on the human microbiome. This partnership is poised to revolutionize clinical insight and decision-making in the pharmaceutical industry, with the goal of improving therapeutic efficacy and commercial longevity. The partnership combines Zymo Research’s expertise in sample preparation and next-generation sequencing with BluMaiden’s advanced bioinformatics capabilities through its proprietary KEYSTONE™ AI analytics platform to explore the human microbiome to discover clinical insights into health and disease. Create seamless solutions that can help you. These insights include, but are not limited to, endpoint optimization, predicting drug responders versus non-responders, and patient enrichment and stratification.

The joint service will cover all steps of human microbiome analysis, including fit-for-purpose sample collection, nucleic acid purification, next-generation sequencing, sophisticated bioinformatics data analysis, and detailed clinical trial reporting. The new service is designed to be applicable to the entire trial cohort across Phase 1, 2, 3, and 4 clinical trials and will apply to a wide range of disease indications and intervention modalities, including those where microbiome data analysis was not previously possible. You can. respected. While the report provides information for early pilot analyses, it is also applicable to subsequent pivotal Phase 2 and 3 clinical trials. Pharmaceutical services can also be applied retroactively by leveraging raw sequence data and metadata for reanalysis.

This comprehensive approach is designed to give pharmaceutical customers easy, affordable and rapid access to high-quality clinical insights, with the goal of accelerating time to market and extending the commercial life of therapeutics.

Dr. Keith Booher, Director of Research Services at Zymo Research Corporation, detailed the strategic importance of the partnership and each company’s efforts to advance microbiome-based discoveries. “By combining the strengths of Zymo Research with BluMaiden Biosciences, we are not only enhancing our service offering but also setting a new standard for microbiome data analysis. This collaboration allows us to deliver unparalleled levels of accuracy and efficiency and support our clients’ research with the most comprehensive insights.”

Dr. Damien Keogh, CEO and Director of BluMaiden Biosciences, also commented on the organization’s shared vision to support the pharmaceutical sector with complete solutions for human microbiome analysis. “We are excited to partner with Zymo Research to bring this innovative pharmaceutical service to the market,” said Keogh. Our joint commitment to excellence and innovation enables us to meet the high-quality and rapidly evolving requirements of the pharmaceutical sector, delivering novel applications of microbiome-based data and translating these insights into patient-specific clinical outcomes. “It will happen.”

The new pharmaceutical service will be available in both Europe and North America from the end of the third quarter of 2024. The two companies are confident that this collaboration will greatly benefit pharmaceutical companies and other companies developing new treatments.

Share This Article